Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
Medexus Announces New License Deal for Topical Terbinafine
Medexus to Participate in 35th Annual Roth Conference
Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022
Medexus Welcomes Two New Board Members
Medexus Secures Public Reimbursement for Cuvposa® in Quebec
Medexus Schedules Third Fiscal Quarter 2023 Conference Call
Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update